These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 11142621

  • 1. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
    Raffi F, Reliquet V, Ferré V, Arvieux C, Hascoet C, Bellein V, Besnier JM, Breux JP, Garré M, May T, Molina JM, Perré P, Raguin G, Rozenbaum W, Zucman D.
    Antivir Ther; 2000 Dec; 5(4):267-72. PubMed ID: 11142621
    [Abstract] [Full Text] [Related]

  • 2. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F, VIRGO Study Team.
    Antivir Ther; 1999 Dec; 4 Suppl 3():83-4. PubMed ID: 16021876
    [Abstract] [Full Text] [Related]

  • 3. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F, Reliquet V, Francois C, Garre M, Hascoet C, Allavena C, Arvieux C, Breux JP, Perre P, Rozenbaum W, Auger S.
    Antivir Ther; 1998 Dec; 3 Suppl 4():57-60. PubMed ID: 10723512
    [Abstract] [Full Text] [Related]

  • 4. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L, Cargnel A, Soranzo ML, Chirianni A, Ferraro T, Di Stefano M, Angarano G.
    Antivir Ther; 1999 Dec; 4(4):195-202. PubMed ID: 10723498
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
    Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S.
    J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230
    [Abstract] [Full Text] [Related]

  • 6. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Jul; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 7. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F.
    HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J.
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [Abstract] [Full Text] [Related]

  • 10. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Nov; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
    Getahun A, Tansuphasawadikul S, Desakorn V, Dhitavat J, Pitisuttithum P.
    J Med Assoc Thai; 2006 Sep; 89(9):1472-8. PubMed ID: 17100387
    [Abstract] [Full Text] [Related]

  • 14. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C, Soriano V, Pérez-Olmeda M, Rodríguez-Rosado R, González-Lahoz J.
    J Hum Virol; 2000 Mar; 3(6):335-40. PubMed ID: 11100914
    [Abstract] [Full Text] [Related]

  • 16. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
    García F, Knobel H, Sambeat MA, Arrizabalaga J, Aranda M, Romeu J, Dalmau D, Segura F, Gomez-Sirvent JL, Ferrer E, Cruceta A, Gallart T, Pumarola T, Miró JM, Gatell JM, Spanish SCAN Study Group.
    AIDS; 2000 Nov 10; 14(16):2485-94. PubMed ID: 11101059
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr 10; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 18. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH, Wensing AM, Hassink EA, ten Kate RW, Richter C, Schreij G, Koopmans PP, Juttmann JR, van der Tweel I, Lange JM, Borleffs JC.
    HIV Clin Trials; 2005 Apr 10; 6(5):235-45. PubMed ID: 16306030
    [Abstract] [Full Text] [Related]

  • 19. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
    Mobley JE, Pollard RB, Schrader S, Adler MH, Kelleher T, McLaren C.
    AIDS; 1999 Jul 30; 13(11):F87-93. PubMed ID: 10449279
    [Abstract] [Full Text] [Related]

  • 20. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM.
    J Antimicrob Chemother; 2009 Feb 30; 63(2):380-8. PubMed ID: 19036752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.